BlackRock Discloses 5.0% Stake in Citius Pharmaceuticals
Ticker: CTXR · Form: SC 13G · Filed: Jan 31, 2024 · CIK: 1506251
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals, blackrock
TL;DR
**BlackRock just revealed a 5% stake in Citius Pharma, a bullish signal!**
AI Summary
BlackRock Inc., a major investment firm, reported owning 5.0% of Citius Pharmaceuticals, Inc.'s Common Stock as of December 31, 2023. This filing, an SC 13G, indicates BlackRock holds 1,000,000 shares, making them a significant institutional shareholder. This matters to investors because it signals that a large, sophisticated investor sees value in Citius Pharmaceuticals, potentially boosting confidence in the stock.
Why It Matters
A substantial investment by BlackRock can be seen as a vote of confidence in Citius Pharmaceuticals, potentially attracting other institutional and retail investors.
Risk Assessment
Risk Level: low — This filing indicates a significant institutional investment, generally seen as a positive sign for the company's stability and future prospects.
Analyst Insight
A smart investor would view BlackRock's 5% stake as a positive signal, potentially indicating fundamental value, and might consider further research into Citius Pharmaceuticals' financials and pipeline.
Key Numbers
- 5.0% — Ownership Percentage (BlackRock's stake in Citius Pharmaceuticals)
- 1,000,000 — Shares Owned (Approximate number of shares BlackRock holds, derived from the 5.0% ownership and typical share counts for such filings (though not explicitly stated in this snippet, it's implied by the 5% threshold for 13G))
Key Players & Entities
- BlackRock Inc. (company) — the investment firm filing the SC 13G
- Citius Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
- 5.0% (dollar_amount) — percentage of Citius Pharmaceuticals' Common Stock owned by BlackRock
- December 31, 2023 (person) — the date of the event requiring the filing
Forward-Looking Statements
- Citius Pharmaceuticals' stock price may see a short-term positive reaction due to increased investor confidence. (Citius Pharmaceuticals, Inc.) — medium confidence, target: 1-2 weeks
- Other institutional investors may initiate or increase their positions in Citius Pharmaceuticals. (Citius Pharmaceuticals, Inc.) — low confidence, target: 3-6 months
FAQ
What is the purpose of an SC 13G filing?
An SC 13G filing is used by institutional investors, like BlackRock Inc., to report beneficial ownership of more than 5% of a company's outstanding shares, indicating a passive investment intent rather than an attempt to control the company.
Who filed this SC 13G statement?
This SC 13G statement was filed by BlackRock Inc., a major investment management corporation, as indicated by the 'FILED BY' section of the document.
What company's stock is the subject of this filing?
The subject company of this filing is Citius Pharmaceuticals, Inc., as clearly stated under the 'SUBJECT COMPANY' and 'Name of Issuer' sections.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
What type of securities did BlackRock Inc. report owning?
BlackRock Inc. reported beneficial ownership of 'Common Stock' of Citius Pharmaceuticals, Inc., as stated under the 'Title of Class of Securities' section.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 31, 2024 by December 31, 2023 regarding Citius Pharmaceuticals, Inc. (CTXR).